IMS Worl orld d Review Executive 2010 TM
20TH ANNIVERSARY EDITION
IMS WORLD REVIEW EXECUTIVE™ EXECUTIVE ™ 2010 Preface IMS World Review ExecutiveTM 2010 provides essential insights into worldwide sales of the pharmaceutical market, interlocking market trends and sales analysis from 2005 to 2009, including the breakdown of sales by regions, countries, therapeutic areas, products and companies. This handy pocket-size guide will give company executives the opportunity to obtain the most accurate and consistent pharmaceutical pharmaceutical sales data available on the market. For its 20th Anniversary, IMS World Review ExecutiveTM has been enhanced to include additional datasets such as insights on Biologics and Generics. The format and layout have also been improved to allow this resource to be recognized as a unique global market overview.
IMS World Review ExecutiveTM also provides critical insights into the future which can be found in the new chapter called: “Goba Parmacetica Otoo to 2014”. A combination of qualitative insights and top line forecasts allow the reader to understand the prognosis of the global pharmaceutical market.
IMS Health 7 Harewood Avenue London NW1 6JB United Kingdom Tel: + 44 203 075 5888 Mail: Service@imsh
[email protected] ealth.com www.imshealth.com
i
The Information Service contained herein is condential and provided subject to the IMS Health Information Services Standard Terms and Conditions. This Information Service is provided to the Client on a personal basis under a non-exclusive and non-transferable licence for the Client’s own direct benet and use only, and may not be copied or divulged to any other party. Whilst every possible care has been taken in the preparation of this information, the publishers do not hold themselve themselves s responsible for any expressions of opinion or error or omission, or any action resulting therefrom. © 2010. IMS Health Incorporated or its afliates. All rights reserved ii
IMS WORLD REVIEW EXECUTIVE™ EXECUTIVE ™ 2010 Tabe of Content PREFACE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . i WORldWIdE Ph PhARMACEuTICAl MA MARkETS - ESTIMATEd MA MARkET . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1 Market Estimates by Region . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .2 Market Estimates for Top 30 Countries . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 Market Estimates for Other IMS Audited Countries . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 REGIONAl & COuNTRY MARkET TRENdS - AudITEd MARkET . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 Worldwide Growth Trends . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 North America Growth Trends . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .12 Europe Growth Trends . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .13 Africa, Asia & Australasia Growth Trends . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 Latin America Growth Trends . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .19 Five Year Growth Rates by Country . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .20 WORldWIdE PhARMACEuTICAl CORPORATIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .25 Top 100 Worldwide Corporations - Worldwide Sales & Regional Market Share . . . . . . . . . . . . . . . . . . . . . . . . . . . 26 Fastest Growing 50 Corporations - Five Year Worldwide Sales Trends . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31 WORldWIdE ThERAPEuTIC AREAS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35 35 Sub-Therapeutic Cl Classes An Analysis - Wo Worldwide Sa Sales & Re Regional Ma Market Sh Share . . . . . . . . . . . . . . . . . . . . . . . . . . . 36 Top 50 50 Th Therapeutic Ar Areas (A (ATC3) - Leading Co Corporations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74 Fastest Gr Growing 100 Therapeutic Areas - Five Year Worldwide Sales Trends . . . . . . . . . . . . . . . . . . . . . . . . . . . 124
iii
IMS WORLD REVIEW EXECUTIVE™ EXECUTIVE ™ 2010 Tabe of Content WORldWIdE PhARMACEuTICAl PROduCTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 131 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 1 31 Top 75 Worldwide Products - Worldwide Sales & Regional Market Share . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 132 Fastest Gr Growing 80 Products - Five Year Worldwide Sales Trends . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 145 Top 50 50 Ne New Ac Active Su Substances - Five Ye Year Wo Worldwide Sa Sales Tr Trends. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 151 Top 50 Biologics - Five Year Worldwide Sales Trends . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 155 Top 50 Generic Products - Five Year Worldwide Sales Trends . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 158 GlOBAl PhARMACEuTICAl OuTlOOk TO 2014 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 167 APPENdICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 169 Estimated Market Universe . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 169 Audited Market Universe & Panels . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 175 IMS New Active Substance Denition . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 183 IMS Ge Generics De Denition. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18 1 85 IMS Biologics Denition. Denition. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18 1 89 Sales Data Measures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19 1 92 CONTACT uS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 195
iv
WORLDWIDE PHARMACEUTICAL MARKETS - ESTIMATED MARKET Introction This section provides a sales data overview of the 2009 world pharmaceutic pharmaceutical al markets, using the Estimated Market Universe. US$ sales values and growth rates from 2005 to 2009 are displayed for all regions as well as for all IMS audited countries, allowing you to understand the performance of each country market and their evolution over the years. To give you as complete a picture as possible, estimated sales through all distribution channels in all countries are shown (Market Estimates by Region), whether these channels are audited by IMS Health or not. These estimates are intended to include both prescription and most non-prescription products. We provide these estimates to put into perspective the information contained in all other sections of IMS World Review Executive ™, which is based on IMS Health audit information only. For any country audited by IMS Health, the total market estimate is based on the audited gure, with allowances made for non-audited sectors of the market, based on information from IMS Health audits. For non-audited markets we have used the technique of reverse evaluation of export statistics, export statistics of the major exporting countries are matched up with local import statistics. Retained local production is added in, to arrive at a total market estimate. Please refer to the Appendices to review all the countries included in the Estimated Market Universe.
1
WORLDWIDE PHARMACEUTICAL MARKETS - ESTIMATED MARKET Maret Estimates by Region
Revise
Revise
Revise
Revise
2009
2008
2007
2006
2005
$ (Bi)
$ (Bi)
$ (Bi)
$ (Bi)
$ (Bi)
North America
3 1 9 .5
304.1
298.6
285.7
261.1
Europe
2 3 6 .7
246.6
217.8
186.3
174.4
Africa, Asia & Australasia
2 0 1 .8
179.2
155.1
137.2
133.5
Latin America
4 8 .7
4 8 .4
4 2 .1
3 5 .9
32.2
TOTAL WORLD MARKET ($ Billion)
8 0 6 .6
778.3
713.6
645.0
601.2
GROWTH OVER PREVIOUS YEAR (%)
3.6%
9 .1 %
1 0 .6 %
7 .3 %
Contry
USD Millions $319,452 North America 39.7%
$48,654 Latin America 6.0%
$236,690 Europe 29.3% $201,795 Africa, Asia & Australasia 25.0%
Worldwide Pharmaceutical Market Estimate 2009 = $806.6 Billion
2
WORLDWIDE PHARMACEUTICAL MARKETS - ESTIMATED MARKET Maret Estimates for Top 30 Contries
2009 Ran
2009 Contry
$ (Mi)
1
United States
300748
2
Japan
3
Germany
2009 Growt (%) $
Revise 2008
lCd
$ (Mi)
5
5
285285
89865
17
6
41275
-2
2008 Growt (%) $
Revise 2007
lCd
$ (Mi)
2
2
280995
77041
17
3
4
41932
12
2007 Growt (%) $
Revise 2006
lCd
$ (Mi)
4
4
270108
65730
3
4
5
37278
16
2006 Growt (%) $
Revise 2005
2005 Growt (%)
lCd
$ (Mi)
$
lCd
9
9
247654
5
5
63711
-6
-1
67741
5
7
6
32076
3
2
31100
7
8
4
France
40575
-5
1
42526
10
3
38495
16
6
33217
4
3
32041
7
7
5
China
31688
29
27
24545
39
27
17698
32
26
13441
16
13
11612
22
20
6
Italy
26857
-1
4
27169
12
4
24234
15
6
20989
5
4
19949
4
4
7
Spain
22818
1
6
22620
16
8
19563
19
9
16486
9
8
15129
8
8
8
United Kingdom
19843
-11
5
22234
-5
3
23368
14
5
20505
6
4
19433
-3
-2
9
Canada
18705
-0
6
18786
7
6
17590
13
6
15549
15
8
13489
15
7
10
Brazil
17403
4
13
16749
22
14
13708
25
11
10957
13
2
9687
37
13
11
Russian Federation
11442
-9
15
12609
38
35
9118
12
5
8132
41
35
5747
50
48
12
India
10405
7
19
9725
4
11
9314
25
13
7463
15
18
65 0 3
12
9
13
Mexico
10399
-17
1
12576
0
2
12525
8
8
11598
5
6
11000
16
12
14
Turkey
10276
-4
16
10660
12
12
9508
29
17
7363
5
12
7009
54
46
15
South Korea
9472
-3
14
9756
-5
10
10287
14
11
9049
20
12
7547
27
13
16
Australia
9423
0
7
9388
11
10
8443
23
11
6843
3
4
6616
9
5
17
Greece
7537
4
10
7254
18
10
6124
28
18
4772
12
11
4249
13
13
18
Venezuela
6626
31
31
5050
33
33
3793
33
33
2862
30
32
2200
18
32
19
Poland
6601
-15
10
7794
27
9
6160
23
9
5022
9
4
4623
21
8
20
Belgium
6208
-2
3
6356
14
6
5565
15
6
4822
2
2
47 09
4
4
21
Netherlands
5417
-8
-3
5914
4
-4
5712
16
7
4909
4
3
4709
3
3
3
REGIONAL & COUNTRY MARKET TRENDS - AUDITED MARKET Introction This section provides a sales data overview of the 2009 world pharmaceutical markets, using the IMS Audited Market Universe. US$ sales values and growth rates from 2005 to 2009 are displayed for all regions. Growth rates based on US$ from 2005 to 2009 are shown for all IMS audited countries, allowing you to understand the performance of each country market and their evolution over the years. IMS Health’s pharmaceutical audits for individual countries serve as the main source of comparative sales data on the pharmaceutical industry.. The audits are continuous, periodic market surveys based on statistically representative industry representative samples, the data from which provide regional and national estimates. In the major countries, the pharmaceutical audits incorporate transaction data from wholesalers giving rise to a near-census of the retail market. Each country audit records the data according to local requiremen requirements. ts. Therefore the way data is collected and held will vary from country to country. In the European countries and America, the majority of pharmaceutic pharmaceuticals als are dispensed or sold mainly through retail pharmacies and drug stores. Thus sampling at the retail pharmacy level in such countries will represent a major proportion of the total market. Consequently, most of the IMS Health audits are sampled through retail pharmacies. There are some exceptions, for example Japan (see Japan section). The audits provide a comprehensive record of purchases of pharmaceuticals in each country. A number of retail pharmacies and wholesalers are chosen for sampling sampling (sample size) and sales data is collected by IMS Health on a regular basis. This data is then projected to estimate sales for the total number of retail pharmacies in a country (this is referred to as the universe universe). ). With some variation in each country, the sales estimates shown represent direct and indirect purchases by retail pharmacies from pharmaceutical wholesalers and manufacturers. It should be noted that, whilst IMS Health data is the most comprehensi comprehensive ve source available to monitor sales through their retail channels, some products are more widely distributed and used in a hospital or clinic environment (for example oncology, oncology, diagnostic or specialist anti-infective anti-infective treatments). For such products, IMS Health retailer-ba retailer-based sed audits do not provide comprehensive coverage, and supplementary supplemen tary data sources will be required to project these data to a total universe for these specialist products. The sales data in IMS World Review Executive ™ is calculated based on sales from manufacture manufacturerr to wholesalers known as the exmanufacturer price.
9
REGIONAL & COUNTRY MARKET TRENDS - AUDITED MARKET Introction In many countries, including USA, Canada, Japan and throughout Latin America, these are estimated weighted average factors, which take into account varying margins and the direct/indire direct/indirect ct sales mix. As market conditions change the conversion factors are updated by the local IMS ofces. Changes in factors are not retroactively applied to historical data. Data is collected in each country in local currency. This is converted into US Dollars using the prevailing average exchange rate for the quarter. Please refer to the Appendices to review all the countries included in the Audited Market Universe.
10
REGIONAL & COUNTRY MARKET TRENDS - AUDITED MARKET Worwie Growt Trens
Growt $ (%) Based on uS$
Worwie
AV Growt **AV Growt
2009 2008 2007 2006 2005 3
8
10
7
8
$ (%) 7
USD Millions
$ (%) 7 800000
+10.0%
NORTH AMERICA
5
2
5
9
6
5
5
-4
12
16
6
8
7
7
A/A/A
12
15
12
2
12
11
11
2
15
17
15
19
13
13
LATIN AMERICA
+6.9%
700000 +7.9%
600000
EUROPE
+7.6%
+12.3%
500000 2005 2005 2006 200 6 2007 2008 2009
400000 300000
$567,969 $567,96 9 $609,52 $609 ,526 6 $670,42 $670 ,422 2 $726,16 $726 ,164 4 $751,02 $751 ,027 7
200000 100000 0 2005
2006
2007
20 08 08
2009
11
WORLDWIDE PHARMACEUTICAL CORPORATIONS Introction This section provides a sales data overview of the 2009 leading pharmaceutical corporations, using the IMS Audited Market Universe. US$ sales values and growth rates from 2005 to 2009 are displayed for the top 100 corporations, as well as their market share in North America, Europe, Africa-Australasia-Asia, and Latin America. Please refer to the Appendices - “Audited Market Universe and Panels” section - to view the countries included in each region. This section also includes the fastest-growing 50 corporations, including US$ sales and growth rates over 2005 to 2009.
25
WORLDWIDE THERAPEUTIC AREAS Introction This section provides a sales data overview of the 2009 leading therapeutic areas, using the IMS Audited Market Universe. US$ sales values and growth rates from 2005 to 2009 are displayed for all therapeutic classes at level 4, as well as their market share in North America, Europe, Africa-Australasia-Asia, and Latin America. Please refer to the Appendices - “Audited Market Universe and Panels” section - to view the countries included in each region. This section also proles the top 50 therapeutic areas at level 3, showing the leading 15 corporations. This is complemented by a view of the fastest-growing 100 therapeutic areas, including US$ sales and growth rates over 2005 to 2009.
35
WORLDWIDE PHARMACEUTICAL PRODUCTS Introction This section provides a sales data overview of the 2009 leading pharmaceutical products, using the IMS Audited Market Universe. US$ sales values and growth rates from 2005 to 2009 are displayed for the top 75 products, as well as their market share in North America, Europe, Africa-Australasia-Asia, and Latin America. Please refer to the Appendices - “Audited Market Universe and Panels” section - to view the countries included in each region. This section also includes the fastest-growing 80 Products, including US$ sales and growth rates over 2005 to 2009. Sales data over 2005 to 2009 is also provided for the top 50 New Active Substances, Generics and Biologics. Please refer to the Appendices to understand how IMS denes New Active Substances, Generics and Biologics.
131
ABOUT IMS
Operating in more than 100 countries, IMS Health is the world’s leading provider of market intelligence to the pharmaceutical and healthcare industries With $2.2 billion in 2009 revenue and more than 50 years of industry experience, IMS offers leading-edge market intelligence products and services that are integral to clients’ day-to-day operations, including product and portfolio management capabilities; commercial commercial effectiv effectiveness eness innovations; managed care and consumer health offerings; and consulting and services solutions that improve productivity and the delivery of quality healthcare worldwide. Additional infor information mation is available at http://www.imshealth.com
IMS HEALTH®
7 Harewood Avenue London NW1 6JB UK Tel: +44 (0)20 3075 5888 www.imshealth.com
